I'd like to go back.
Madam Yeates, in your presentation you spoke about the backlog for new drug submissions and about how it had been eliminated in 2011, but you talked about the challenge in meeting performance targets for generic drug reviews.
Is there anything specific to a generic review that has caused a delay in meeting these performance targets? Or does it simply happen to be one of those situations in which you were dealing with one part and hadn't gotten around to the other?